Bicara Therapeutics Inc. (BCAX)
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$137.9M
- Total assets
- $431.0M
- Market cap
- $1.8B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $155.6M
- Operating income
- -$155.6M
- Income tax
- $217.0K
- Net income
- -$137.9M
- EPS (basic)
- $-2.52
- EPS (diluted)
- $-2.52
Balance sheet
- Total assets
- $431.0M
- Current assets
- $422.1M
- Total liabilities
- $29.5M
- Current liabilities
- $28.9M
- Shareholders’ equity
- $401.5M
Cash flow
- Operating cash flow
- -$106.8M
- Investing cash flow
- -$318.5M
- Financing cash flow
- $32.3M
- Net cash flow
- -$393.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.8B
- EPS (diluted)
- $-2.52
- Shares outstanding
- 48.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 13, 2024
Bicara Therapeutics Inc. (BCAX) Stock Price
- Reported a net loss of $137.9M.
- Trading 11% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Bicara Therapeutics Inc..
Write a review
News about Bicara Therapeutics Inc.
News & sentiment via Polygon.io
Bicara Therapeutics Inc.: frequently asked questions
Is Bicara Therapeutics Inc. an American company?
Bicara Therapeutics Inc. is a US-based company headquartered in Boston, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Bicara Therapeutics Inc. headquartered?
Bicara Therapeutics Inc. is headquartered in Boston, Massachusetts, United States.
Is Bicara Therapeutics Inc. publicly traded?
Yes — Bicara Therapeutics Inc. is a publicly traded company. Its stock trades under the ticker symbol BCAX on the NASDAQ.
What does Bicara Therapeutics Inc. do?
Bicara Therapeutics Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
